fbpx
Pharmaceutical, Biotechnology, and Medical Devices Litigation
OVERVIEW

Seasoned patent litigators with extensive trial experience in pharmaceutical and biotechnology cases are at the center of Maynard Cooper’s intellectual property practice. Our lawyers have a  successful track record in many patent actions involving Abbreviated New Drug Applications (ANDA) under the Hatch-Waxman Act directed to dozens of different small and large molecules.

Lawyers on our patent litigation team have represented both generic and branded pharmaceutical companies in cases involving some of their most important drugs. Examples of  the small and large molecules that have been the subject of  patent actions litigated by our lawyers include high profile pharmaceuticals and biologics such as Oxycodon/Oxycontin, Sildenafil/Viagra, Filgrastim/Neupogen, Tramadol/Ultram, Epinephrine/EpiPen, Pramipexole/Mirapex, Nitrofurantoin/Macrobid, Timolol Maleate/Timoptic, Hepatitis C Protease, Tobramycin/Tobi and Interferon.

The firm’s patent litigators appear regularly before the federal district courts in Hatch-Waxman matters and have successfully argued appeals to the U.S. Court of Appeals for the Federal Circuit. Many of the lawyers on our team are registered to practice in the United States Patent and Trademark Office and represent clients in Patent Office proceedings and trials, including inter partes review (IPR) and post-grant invalidity challenges under the America Invents Act.

Maynard Cooper lawyers also advise pharmaceutical and biotechnology clients in a wide range of areas, including biologics, biosimilars, pharmaceuticals, medical devices, diagnostic technologies and drug delivery systems. Our team includes a number of lawyers with advanced scientific degrees who stand by our clients at the intersection of complex scientific and clinical issues and the law, enabling our litigators to simplify the presentation of complex arguments and provide clients with winning results in the courts and other tribunals. Our lawyers know the science and the technology, focus on the business concerns of our clients, and work closely with our clients to develop effective litigation strategies tailored to each matter that often lead to favorable settlements before trial. We are client-driven with decades of experience advising both large and small pharmaceutical and biotech companies in all aspects of their businesses, and we are committed to providing excellent service at an uncommon value so that our clients can meet their business objectives in an efficient and cost effective way.

PRIMARY CONTACTS
July 14, 2020
New Title IX Rules Take Effect in 30 Days

The new Title IX rules issued by the U.S. Department of Education (the “Department”) in May become effective on August 14, 2020, just one month from now.  Even though the new rules are facing several legal challenges, the effective date…

July 8, 2020
SEC Snapshots Q2 2020

The members of Maynard Cooper’s Public Company Advisory Practice counsel public companies, as well as companies aiming to become public, on the full range of matters shaping their operation in the public markets. As a continued service to our clients,…